[HTML][HTML] Randomized open-label phase II study of decitabine in patients with low-or intermediate-risk myelodysplastic syndromes
G Garcia-Manero, E Jabbour, G Borthakur… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
G Garcia-Manero, E Jabbour, G Borthakur, S Faderl, Z Estrov, H Yang, S Maddipoti…
Journal of clinical oncology, 2013•ncbi.nlm.nih.govRandomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk
Myelodysplastic Syndromes - PMC Back to Top Skip to main content NIH NLM Logo Access
keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC4878053
Other Formats PubReader PDF (141K) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J …
Myelodysplastic Syndromes - PMC Back to Top Skip to main content NIH NLM Logo Access
keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC4878053
Other Formats PubReader PDF (141K) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J …
Abstract
Purpose
This open-label, randomized phase II trial assessed efficacy and tolerability of two low-dose regimens of subcutaneous (SC) decitabine in patients with low-or intermediate-1–risk myelodysplastic syndrome (MDS).
ncbi.nlm.nih.gov